How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam Pharmaceuticals.

Investors Business Daily • Dec 2, 2025

BridgeBio to Participate in December Investor Conferences

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

GlobeNewsWire • Nov 25, 2025

Biotech Stock Could Turn 4-Year Peak Into Records

BridgeBio Pharma Inc   (NASDAQ:BBIO) stock is up 3.3% to trade at $70.36 at last check, and earlier hit a fresh four-year high $70.60 on a bounce off its 20-day moving average.

Schaeffers Research • Nov 24, 2025

BridgeBio Pharma: Set For New Commercial Launches After Trial Successes

BridgeBio has surged 90% since April 2025, driven by major clinical trial successes and robust commercial execution. BBIO's BBP-418 and Encaleret trials both exceeded expectations, each targeting billion-dollar rare disease markets with little competition. Attruby's commercial launch continues to outperform, capturing valuable first-line market share and supporting long-term growth prospects.

Seeking Alpha • Nov 23, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company's common stock.

GlobeNewsWire • Nov 19, 2025

BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript

BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wade Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma.

Seeking Alpha • Nov 11, 2025

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk reduction in ACM/ first CVH through Month 30 compared to placebo (p=0.016) and a 69% risk reduction in ACM through Month 42 (p=0.045) in ATTR-CM participants with the genetic variant p.Val142Ile (V142I, V122I) compared to patients initially randomized to placebo in the ATTRibute-CM study - This is the first report of clinical benefit of this magnitude observed in this high-risk population with significant unmet need PALO ALTO, Calif., Nov. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, presented data from the ATTRibute-CM study, showing that acoramidis significantly reduces all-cause mortality (ACM) through Month 42 in the overall variant ATTR-CM population, and specifically in the p.Val142Ile (V142I, V122I) subpopulation.

GlobeNewsWire • Nov 8, 2025

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry.

GlobeNewsWire • Nov 7, 2025

BridgeBio to Participate in November Investor Conferences

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:

GlobeNewsWire • Nov 4, 2025

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025.

GlobeNewsWire • Nov 3, 2025